参附注射液对全身炎症反应综合征的临床干预作用及机制研究 |
| |
引用本文: | 黄兰兵,;杨欣建. 参附注射液对全身炎症反应综合征的临床干预作用及机制研究[J]. 深圳中西医结合杂志, 2014, 0(7): 7-9 |
| |
作者姓名: | 黄兰兵, 杨欣建 |
| |
作者单位: | [1]安徽医科大学深圳二院临床学院,广东深圳518035; [2]深圳市第二人民医院,广东深圳518035 |
| |
基金项目: | 广东省医学科研基金项目(B2009223) |
| |
摘 要: | 目的:探讨参附注射液对全身炎症反应综合征(SIRS)的临床干预作用及对核因子-κB(NF-κB)活性的影响,以初步阐明其机制。方法:选取我院满足SIRS纳入标准的患者18名,随机分为3组:空白对照组、生理盐水治疗组和参附注射液(SF)治疗组,每组6例。经相应治疗后,采用酶联免疫法(ELISA)分别检测各组患者不同时间点血液中单个核细胞NF-κB、血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平变化。结果:参附注射液治疗组患者血NF-κB、TNF-α、IL-6水平第1天达最高水平,随后逐渐下降,与空白对照组及生理盐水组比较具有显性差异(P0.05)。结论:参附注射液可能通过减少NF-κB的激活,降低TNF-α和IL-6的释放,进而减轻肺脏和肝脏的病理损伤,对全身炎症反应综合征起保护作用。
|
关 键 词: | 参附注射液 全身炎症反应综合征 核因子κB 肿瘤坏死因子-α 白介素-6 |
The Study of Clinic Intervention Effect of Shenfu Injection on Systemic Inflammatory Response Syndrome and its Mechanism |
| |
Affiliation: | HUANG Lan-bing,YANG Xin-jian (1. The Clinical College of Shenzhen Second People's Hospital, Anhui Medical University, Guangdong Shenzhen 518035; 2 Shenzhen Second People's Hospital, Guangdong Shenzhen 518035) |
| |
Abstract: | Objective To study the clinic intervention effect of Shenfu injection(SF) on systemic inflammatory response syndrome (SIRS) and the activity of nuclear factor-κB (NF-κB), and initially elucidate its mechanism. Methods The 18 patients in our hospital met the inclusion criteria of SIRS were randomly divided into three groups: the control group, the normal sodium(NS) group and the SF treatment group, with 6 cases in each group. After treating respectively, the levels of blood mononuclear cell nuclear factor-κB(NF-κB), serum tumor necrosis factor -α (TNF-α), interleukin -6 (IL-6) at different time point were all detected by using euzymelinked immunosorbent assay(ELISA) technique. Results The blood levels of NF-κB, TNF-α, IL-6 in SF treatment group were increased to the highest level at the first day, then they were fallen-off gradually. Compared with the control group and the normal sodium(NS) group, the differences were statistically significant (P〈 0.05). Conclusion SF injection can reduce the activation of NF-κB, decrease the release of TNF-α and IL-6, and then alleviate the pathological damage of lung and liver, so play a role of protection for patients with SIRS. SF injection has a certain therapeutic effect on SIRS. |
| |
Keywords: | Systemic inflammatory response syndrome Nuclear factor-κB Shenfu injection Tumor necrosis factor-α Interleukin -6 |
本文献已被 CNKI 维普 等数据库收录! |
|